연구용역

Biomedcode (관절염)

Arthritis

Biomedcode Hellas SA

홈페이지 바로가기

Preclinical Efficacy Platforms

in-vivo standardized preclinical platforms of arthritis, intestinal inflammation, psoriasis, osteoporosis and other inflammatory diseases

Therapeutic areas - Animal models

  • Spondyloarthritis – mouse tmTNF driven spondyloarthritis (TgA86)
  • Osteoporosis – human RANKL transgenic mice (TghRANKL)
  • Rheumatoid Arthritis
    Human TNF driven polyarthritis (Tg197)
    Human tmTNF driven arthritis (Tg5453)
    Human TNF driven slow progressing arthritis (Tg3647)
    Human TNF-TNFR1 driven arthritis (Tg197hTNFR1KI)
    Mouse TNF driven spondyloarthritis (TNFΔARE)
    Collagen Antibody Induced Arthritis (CAIA)
    Human TNF driven CAIA
  • Inflammatory Bowel Disease (IBD)
    Mouse TNF driven spondylitis (TNFΔARE)
    Human TNF dependent TNBS colitis
  • Multiple Sclerosis (MS)
    MOG-induced EAE in wild type mice
    MOG-induced EAE in human TNFR1 knock-in mice
  • Psoriasis
    IMQ-induced psoriasis in wild type mice
    IMQ-induced psoriasis in human IL17A transgenic

Complex mouse disease models developing comorbidities

Biomedcode offers preclinical testing using complex mouse models closely recapitulating the complexity of human disease as they also exhibit co-developing pathologies also observed in human patients.

Humanized targets

Biomedcode has an array of humanized models ideal for the preclinical testing of therapeutics targeting human molecules with no cross-species reactivity.

  • Human TNF
  • Human TNFR1
  • Human RANKL
  • Human IL17A

Acute inflammation

Small doses of endotoxin induce in mice acute inflammatory responses similar to those occuring during the early stages of septic shock.

  • LPS acute sepsis (Cytokine release)
  • GalN – LPS hepatic

Customized Service

  • in vivo pharmacokinetic (PK) studies
  • GalN – LPS hepatic
  • Histology
  • Consulting